Piper Sandler analyst Edward Tenthoff initiated coverage of Galera Therapeutics with an Overweight rating and $6 price target. Galera is developing small molecule superoxide dismutase mimetics for use in combination with radiation therapy for cancer, the analyst tells investors in a research note. The analyst says dismutase mimetics rapidly convert superoxide into hydrogen peroxide to prevent damage to healthy tissue and potentially increase efficacy of radiation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRTX:
- Galera Therapeutics upgraded to Buy from Underperform at BofA
- Galera Therapeutics sells 14.32M shares at $2.095 in registered direct offering
- Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
- Galera announces FDA acceptance, priority review of Avasopasem NDA
- Biotech Alert: Searches spiking for these stocks today